arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Tilray Brands, Inc.

TLRY
$4.58 ▲ +0.13 (+2.92%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
39 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Tilray Brands, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap
Dividend Yield
Revenue Growth 25.5%
Op. Margin -5.8%
ROIC -1.7%
FCF / Share None
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$281.71M
↑ +25.5%
Net Income Profit after all expenses
$-49.57M
↑ +96.1%
Operating Margin Operating profit as % of sales
-5.8%
↑ +54.2% 17th
FCF / Share Free cash flow per share
$-0.19
↓ -151.7%
Long-Term Debt Long-term obligations
$185.70M
↓ -3.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
29
Financial Health
66
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 39 quarters